USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
The Contract Research, Development, and Manufacturing Organization Business Model to Drive Future Growth Potential
15-Feb-2022
North America
Market Research
PCA1-01-00-00-00
HC03504-NA-MT_26275
Frost & Sullivan provides comprehensive insights into the global biologics contract development and manufacturing organization (bio-CDMO) market, including emerging trends, growth opportunities, and profiles of leading bio-CDMOs and their business model evolution. The growth of next-generation biologics and personalized therapies and the emergence of small and midsize biotechnology companies drive bio-CDMOs toward becoming end-to-end integrated service providers for better customer value creation. Next-generation biologics require outsourcing in the early stages of development. With limited or no in-house bioprocess development capacity for new modalities, big pharmaceutical firms and small and emerging biotechnology companies seek outsourcing for these services. To support the outsourcing demand, bio-CDMOs expand to provide contract research services, leading to their adoption of the CRDMO model: contract research, development, and manufacturing.
Company profiles included in this research service offer a brief overview of the bio-CDMO’s value proposition and strategic analysis. The report also emphasizes key strategic collaborations and expansion plans across the biopharmaceutical market. Recent expansion activities in the market reflect the increasing role of bio-CDMOs as a strategic partner in developing new modalities. Bio-CDMOs build capacity and capability to support modalities such as cell and gene therapy and mRNA. The biopharmaceutical market is skewed toward these modalities following the success of mRNA technology in COVID-19 vaccines and therapeutics.
Research Highlights
The research service also highlights the following:
- Role of bio-CDMOs in COVID-19 vaccine scale-up
- Key trends shaping the bio-CDMO industry
- In-house versus outsourcing manufacturing capacity of biologics
- Key themes driving collaborations/expansions
- Recent notable acquisitions and capacity expansions by leading bio-CDMOs
Author: Surbhi Gupta
Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top Three Strategic Imperatives on the Global Biologics CDMO (Bio-CDMO) Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Scope of Analysis
Key Trends Shaping the Bio-CDMO Industry
Growth Drivers
Growth Restraints
Role of Bio-CDMOs in COVID-19 Vaccine Scale-Up
Key Manufacturing Partnerships with Bio-CDMOs for Approved COVID-19 Vaccines—United States
Key Manufacturing Partnerships with Bio-CDMOs for Approved COVID-19 Vaccines—Europe
In-House versus Outsourcing Manufacturing Trends
Key Themes Driving Bio-CDMO Collaborations/Expansions
Recent Notable Acquisitions
Capacity Expansion Plans—Tier I Companies
Capacity Expansion Plans—Tier I Companies (continued)
Capacity Expansion Plans—Tier I Companies (continued)
Capacity Expansion Plans—Tier II/III Companies
Capacity Expansion Plans—Specialized CDMOs and Other Companies
Transition from CDMO to CRDMO
Business Overview
Revenue and Technology Overview
Value Proposition
Strategic Analysis
Business Overview
Revenue and Technology Overview
Value Proposition
Strategic Analysis
Business Overview
Revenue and Technology Overview
Value Proposition
Strategic Analysis
Business Overview
Revenue and Technology Overview
Value Proposition
Strategic Analysis
Business Overview
Revenue and Technology Overview
Value Proposition
Strategic Analysis
Business Overview
Revenue and Technology Overview
Value Proposition
Strategic Analysis
Business Overview
Value Proposition
Strategic Analysis
Business Overview
Revenue and Technology Overview
Value Proposition
Strategic Analysis
Growth Opportunity 1—Strategic Partnerships to Facilitate the Transition from CDMO to CRDMO
Growth Opportunity 1—Strategic Partnerships to Facilitate the Transition from CDMO to CRDMO (continued)
Growth Opportunity 2—Expand Manufacturing Capacity for pDNA
Growth Opportunity 2—Expand Manufacturing Capacityp (continued)
Growth Opportunity 3—Small-scale Agility to Support Specific CGT Needs of Emerging Biopharma Companies
Growth Opportunity 3—Small-scale Agility to Support Specific CGT Needs of Emerging Biopharma Companies (continued)
List of Exhibits
List of Exhibits (continued)
Legal Disclaimer
List of Figures
- Bio-CDMO: Growth Drivers, Global, 2021–2026
- Bio-CDMO: Growth Restraints, Global, 2021–2026
- Bio-CDMO: Notable Acquisitions, Global, 2020–2021
- Bio-CDMO: Capacity Expansion Plans of Tier I Companies, 2020–2021
- Bio-CDMO: Capacity Expansion Plans of Tier II/III Companies, 2020–2021
- Bio-CDMO: Capacity Expansion Plans of Specialized CDMOs and Other Companies, 2020–2021
- Bio-CDMO: Evolving CDMO Value Chain, Global, 2001–Beyond 2020
- Bio-CDMO: Lonza – Group Revenue, Global, 2016–2020
- Bio-CDMO: Lonza – Segment Revenue, Global, 2020
- Bio-CDMO: Samsung Biologics – Revenue, Global, 2016–2020
- Bio-CDMO: BI BioXcellence™ – Biologics Revenue, Global, 2016–2020
- Bio-CDMO: BI Group – Segment Revenue, Global, 2020
- Bio-CDMO: Thermo Fisher Scientific – Group Revenue, Global, 2016–2020
- Bio-CDMO: Thermo Fisher Scientific – Segment Revenue, Global, 2020
- Bio-CDMO: WuXi Biologics, CDMO Revenue, Global, 2016–2020
- Bio-CDMO: Catalent – Segment Revenue, Global, 2020
- Bio-CDMO: Catalent – Group Revenue, Global, 2016–2020
- Bio-CDMO: WuXi AppTec – CDMO Segment Revenue, Global, 2017–2020
- Bio-CDMO: WuXi AppTec – Group Revenue, Global, 2016–2020
Speak directly with our analytics experts for tailored recommendations.
Recent related Life Sciences research
13 Jan 2025 | Global | Market Outlook
Top 6 Growth Opportunities for the Digital Health Industry, 2025
Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...
17 Dec 2024 | Global | Market Research
Cybersecurity in Healthcare, United States, 2024
Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...
12 Dec 2024 | Global | Market Outlook
Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025
Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...
05 Dec 2024 | Global | Frost Radar
Frost Radar™: Enterprise Conversational AI in Healthcare, 2024
This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-care, a...
27 Nov 2024 | Global | Market Research
Generative AI in Payer and Provider IT Transformation, Global, 2024-2029
The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
Research Highlights
The research service also highlights the following:
- Role of bio-CDMOs in COVID-19 vaccine scale-up
- Key trends shaping the bio-CDMO industry
- In-house versus outsourcing manufacturing capacity of biologics
- Key themes driving collaborations/expansions
- Recent notable acquisitions and capacity expansions by leading bio-CDMOs
Author: Surbhi Gupta
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| List of Charts and Figures | Bio-CDMO: Growth Drivers, Global, 2021–2026~ Bio-CDMO: Growth Restraints, Global, 2021–2026~ Bio-CDMO: Notable Acquisitions, Global, 2020–2021~ Bio-CDMO: Capacity Expansion Plans of Tier I Companies, 2020–2021~ Bio-CDMO: Capacity Expansion Plans of Tier II/III Companies, 2020–2021~ Bio-CDMO: Capacity Expansion Plans of Specialized CDMOs and Other Companies, 2020–2021~ Bio-CDMO: Evolving CDMO Value Chain, Global, 2001–Beyond 2020~ Bio-CDMO: Lonza – Group Revenue, Global, 2016–2020~ Bio-CDMO: Lonza – Segment Revenue, Global, 2020~ Bio-CDMO: Samsung Biologics – Revenue, Global, 2016–2020~ Bio-CDMO: BI BioXcellence™ – Biologics Revenue, Global, 2016–2020~ Bio-CDMO: BI Group – Segment Revenue, Global, 2020~ Bio-CDMO: Thermo Fisher Scientific – Group Revenue, Global, 2016–2020~ Bio-CDMO: Thermo Fisher Scientific – Segment Revenue, Global, 2020~ Bio-CDMO: WuXi Biologics, CDMO Revenue, Global, 2016–2020~ Bio-CDMO: Catalent – Segment Revenue, Global, 2020~ Bio-CDMO: Catalent – Group Revenue, Global, 2016–2020~ Bio-CDMO: WuXi AppTec – CDMO Segment Revenue, Global, 2017–2020~ Bio-CDMO: WuXi AppTec – Group Revenue, Global, 2016–2020~ |
| Author | Surbhi Gupta |
| Industries | Healthcare |
| WIP Number | PCA1-01-00-00-00 |
| Is Prebook | No |
| GPS Codes | 9600-B1,9825-B1,9A06-B1,9562-B1,9571-B1,9573-B1,99BF-B1,99C0-B1,99C1-B1,99C6-B1,99C9-B1,99CB-B1,9568-B1,9611-B1,9627-B1 |
Global Biologics Contract Development and Manufacturing Organization Profiles and Growth Opportunities
$2,450.00
Special Price $1,837.50 save 25 %